Mass General's Cancer Center is a world pioneer in personalized cancer therapy, which matches molecularly targeted medications to genetic defects that allow cancer cells to grow. This genotype-based strategy for medication development permits clinical trials to begin earlier in the disease's progression, providing patients more hope for better results.
The Termeer Center for Targeted Medicines is a trailblazer in developing genetically targeted cancer therapies. The Termeer Center, located at the Mass General Cancer Center, is a group of highly competent scientists and clinicians involved in 29 therapy projects and caring for patients at the Center.
The institute performs clinical studies of novel investigational medications that target chemicals that promote cancer development, progression, and dissemination. These treatments may include immunotherapy, chemotherapies, and targeted therapies targeting particular genes linked to the cancer type.
The Termeer Center researches to discover malignancies that are genetically responsive to molecularly targeted therapy and to select individuals for clinical trials. This genotype-based strategy is far faster than traditional clinical trials and allows researchers to examine these medications across several cancer types.
The institute is partly funded by a $10 million contribution from Henri Termeer, former CEO of the biotechnology business Genzyme Corporation. He intends to match the contribution with an extra $10 million from Boston-area benefactors.
The Center for Molecular Therapeutics brings together laboratory-based scientists and clinicians at the Karmanos Cancer Institute to uncover novel molecules, targets, or tactics that improve cancer therapy. Molecular Therapeutics research focuses on four major areas: structural biology, drug discovery and development, pharmacology, pharmacogenomics, and oncogenic signaling.
The Molecular Therapeutics group employs structural biology, machine learning, computational approaches, and biophysics to find new chemicals, antibodies, and small molecule delivery systems that may interest doctors in their quest to enhance patients' lives. To further comprehend protein structure, molecular therapy researchers use X-ray crystallography, NMR, and other modern methods.
The Molecular Therapeutics program of the Indiana Clinical and Translational Sciences Institute assists researchers by serving as a clearing house for drug development resources, such as compound library sharing and collaborative translational research collaborations. It also encourages investigations on absorption, distribution, metabolism, and excretion-toxicology to help transition from drug discovery to commercialization.
The Center for Experimental Therapeutics (ET) is a central point for connecting and coordinating fundamental scientific findings with translational research and clinical trials. The objective is to enhance patient outcomes by accelerating the translation of laboratory findings into viable medicines.
Cancer biologists and experts in biomedical imaging, genetics, and proteomics make up the ET team. These researchers collaborate to create novel cancer medicines based on new molecular targets and improve established treatments such as surgery and chemotherapy.
The Center's members use a mix of tissue, blood, and imaging biomarkers to create novel techniques to anticipate the response of developing anticancer therapies and their interaction with systemic therapy modalities to tailor care and maximize results.
The ETCTN is a nationwide cooperation of academic institutions, pharmaceutical corporations, and independent researchers engaged in early-stage experimental therapeutic clinical trials. The ETCTN is the country's biggest single-institutional partnership, including more than 60 research teams and hundreds of investigators.
The T32 Program supports pre-doctoral and post-doctoral trainees with a cellular and molecular biology background. They gain guided research experience and didactic and seminar instruction during their Program.
This training grant offers a once-in-a-lifetime chance to teach physicians and/or Ph.D. scientists to be independent cancer prevention and control research investigators. This integrative approach to training prepares researchers for employment in academic medicine and industry.
Annually, trainees may apply for up to six T32 training slots. They will be provided stipends and travel allowances to attend T32-related conferences, seminars, and other activities.